755039-80-6

Basic information

• Product Name: Benzenemethanamine, N-[trans-4-(4-morpholinyl)cyclohexyl]-N-(phenylmethyl)-
• CAS NO: 755039-80-6
• Molecular Formula: C24H32N2O
• Molecular Weight: 364.531
• Mol File: 755039-80-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzenemethanamine, N-[trans-4-(4-morpholinyl)cyclohexyl]-N-(phenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanamine, N-[trans-4-(4-morpholinyl)cyclohexyl]-N-(phenylmethyl)-(755039-80-6)
• EPA Substance Registry System: Benzenemethanamine, N-[trans-4-(4-morpholinyl)cyclohexyl]-N-(phenylmethyl)-(755039-80-6)

Safety Data

• Hazardous Substances Data: 755039-80-6(Hazardous Substances Data)

Upstream product

• 110-91-8 morpholine 
• 149506-79-6 4-(dibenzylamino)cyclohexanone 
• 755039-81-7 trans-1-amino-4-dibenzylaminocyclohexane 
• 111-44-4 3-oxa-1,5-dichloropentane 

Downstream Products

• 558442-97-0 (1r,4r)-4-(morpholin-4-yl)cyclohexan-1-amine 
• 412356-24-2 trans-4-morpholinocyclohexan-1-amine hydrochloride 

Relevant articles and documents

Storage stable perfusion solution for dihydropteridinones

Disclosed are storage stable aqueous infusible or injectable solutions containing an active substance of general formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and in the specification, and an amount of a physiologically acceptable acid or mixture of acids sufficient to dissolve the active substance and act as a stabiliser, optionally together with other formulating excipients suitable for parenteral administration, and a process for preparing the infusible or injectable solutions according to the invention.

New pteridinones as PLK inhibitors

Disclosed compounds of general formula (1) wherein L, Q1, Q2, X, Y, Ra, Rb, Rc, R1, R2, R3 and R4 are defined as in claim 1, which are suitable for the trea

DIHYDROPTERIDINONES, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS

The invention relates to novel dihydropteridinones of general formula (I), wherein rests L, R1-R5 have the significance indicated in claims and a specification, in the isomers thereof, in a method for producing and using said dihydropteridinones in the form of drugs.